H.C. Wainwright reiterates Buy on BridgeBio stock, cites cardiac data
H.C. Wainwright reiterated a Buy rating and $120 price target on BridgeBio Pharma (BBIO) after positive cardiac data from its muscular dystrophy treatment. The stock is currently at $66.14, with analysts maintaining a Strong Buy consensus and targets ranging from $80 to $157. BridgeBio reported 202% revenue growth and 94% gross margins over the last year, according to InvestingPro.
How this was made
The 30-second read
Why it matters
The interim cardiac data suggest disease‑modifying benefits, which could accelerate FDA approval and expand the market opportunity.
Market read
New trial data may trigger a short‑term rally in BBIO and positively influence related biotech stocks.
What to watch
Potential competition from other gene‑therapy programs and the timing of the PDUFA decision.
Background
BridgeBio Pharma (NASDAQ:BBIO) focuses on rare genetic diseases. The FORTIFY trial targets LGMD2I/R9, a rare muscular dystrophy.
Ticker impact
BridgeBio Pharma presented new cardiac data from its Phase 3 FORTIFY trial, prompting analysts to reiterate Buy ratings and raise price targets.
likely upward pressure as the market prices in the potential FDA approval.
The data are fresh, first‑reported in this article, and directly support higher valuation multiples.
Market effects
Positive biotech trial data can lift sentiment across rare‑disease and gene‑therapy stocks.
U.S. biotech sector may see modest gains.
Limited to investors tracking clinical‑trial outcomes.
Counterpoint
If the data do not translate into a clear regulatory pathway, the stock could face disappointment.
Key entities
- CompanyBridgeBio Pharma
Biotech firm developing treatments for rare diseases.
- Analyst FirmH.C. Wainwright
Reiterated Buy rating and $120 price target.
